Holen Sie sich die Stockscreener-App
9.20
1.21%
0.11
Actuate Therapeutics Inc Aktie (ACTU) Neueste Nachrichten
Actuate Therapeutics Hosts Key Opinion Leader Event - TipRanks
Actuate Therapeutics (NASDAQ:ACTU) Price Target Raised to $20.00 at HC Wainwright - Defense World
Actuate Therapeutics shares highlights from KOL eventon elraglusib data - Yahoo Finance
Promising Clinical Trial Results Justify Buy Rating for Actuate Therapeutics’ Elraglusib - TipRanks
2 Biopharmaceutical Stocks Focused on Cancer That Wall Street Predicts Will More Than Double - Barchart.com
Actuate Therapeutics Shares Highlights from KOL Event on - GlobeNewswire
Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer - Yahoo Finance
Actuate Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Acral Lentiginous Melanoma Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working In The Therapeutics Segment Delveinsight - MENAFN.com
Actuate Therapeutics, Inc. (ACTU)’s Elraglusib Elraglusib Trial Hits Key Goals in Pancreatic Cancer - Insider Monkey
Actuate Therapeutics: Elraglusib trial meets key endpoint in pancreatic cancer (ACTU:NASDAQ) - Seeking Alpha
Actuate Therapeutics Presents Topline Elraglusib Phase 2 - GlobeNewswire
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer - GlobeNewswire Inc.
P2P Group And NATO Registered Partner Aliter Showcases Inturai Stealthwave Video - The Globe and Mail
Actuate Therapeutics Elects Directors at Annual Meeting - TipRanks
Actuate Therapeutics Reports Phase 2 Trial Success Showing Improved Survival in Metastatic Pancreatic Cancer - Nasdaq
Actuate Therapeutics Announces Details for 2025 ASCO Annual - GlobeNewswire
BIOS Capital Management LP Takes $78.75 Million Position in Actuate Therapeutics (NASDAQ:ACTU) - Defense World
Mercer Global Advisors Inc. ADV Acquires New Shares in Actuate Therapeutics (NASDAQ:ACTU) - Defense World
Apple Is Threatening to Challenge Alphabet's Empire: Is the Stock a Buy? - The Globe and Mail
Adding elraglusib seen to improve survival in pancreatic cancer trial - Rare Cancer News
Analysts Are Bullish on Top Healthcare Stocks: Lineage Therap (LCTX), Tenon Medical, Inc. (TNON) - The Globe and Mail
BlossomHill Therapeutics Appoints Jason Keyes as Chief Financial Officer and Executive Vice President - The Manila Times
Envestnet Asset Management Inc. Invests $83,000 in Actuate Therapeutics (NASDAQ:ACTU) - Defense World
Managing Adverse Events in Pembrolizumab Therapy for Gastric Cancer - Targeted Oncology
Actuate jumps as lead drug succeeds in mid-stage trial for pancreatic cancer - MSN
Theriva’s VCN-01 improves survival in phase IIb pancreatic cancer trial - BioWorld MedTech
Actuate Therapeutics to Host KOL Event on Topline Phase 2 - GlobeNewswire
Actuate Therapeutics to host KOL event on Phase 2 elraglusib data - TipRanks
Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting - Yahoo Finance
PTC hits Huntington biomarker, but approval path still uncertain - biocentury.com
Lilly to pay up to $415M in ALS deal; Actuate’s mid-stage pancreatic cancer data - Endpoints News
Actuate Therapeutics Reports Positive Data From Phase 2 Study Of Elraglusib In Pancreatic Cancer - Nasdaq
Actuate Therapeutics Announces Positive Phase 2 Trial Results - TipRanks
Actuate stock jumps after cancer trial data (ACTU:NASDAQ) - Seeking Alpha
Elraglusib shows survival benefit in pancreatic cancer trial - Investing.com Australia
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer - GlobeNewswire
Elraglusib shows survival benefit in pancreatic cancer trial By Investing.com - Investing.com South Africa
Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025 - GlobeNewswire
Craig-Hallum Sticks to Their Buy Rating for Actuate Therapeutics, Inc. (ACTU) - The Globe and Mail
Why Are Young Adults Getting More Pancreatic & Colon Cancer? - Targeted Oncology
Younger Adults See Sharp Rise in Pancreas & Colon Cancer, Study Shows - Targeted Oncology
Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
Actuate Therapeutics to Present Topline Phase 2 Data of Elraglusib at 2025 ASCO Annual Meeting - Nasdaq
Actuate to Present Elraglusib Phase 2 Topline Data at the - GlobeNewswire
Actuate Therapeutics (NASDAQ:ACTU) Now Covered by Analysts at Craig Hallum - Defense World
Craig-Hallum sets $21 target on Actuate Therapeutics stock By Investing.com - Investing.com Canada
3 No-Brainer Artificial Intelligence (AI) Stocks to Buy Before Earnings Season Heats Up - The Globe and Mail
What Will Actuate Therapeutics Inc (NASDAQ: ACTU) Be Like In 2025 - stocksregister.com
Pre-market Movers: CHRO, QURE, FOTA, LLY... - RTTNews
Actuate Therapeutics to Present Elraglusib Data for Advanced Salivary Gland Carcinoma at AACR Annual Meeting 2025 - Nasdaq
Actuate to Present Promising Data on Elraglusib in Advanced - GlobeNewswire
Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025 - Yahoo Finance
Disparities in Treatment/Survival Outcomes Observed in Metastatic PDAC - CancerNetwork
Actuate Therapeutics (NASDAQ:ACTU) Trading 6% Higher – Still a Buy? - Defense World
Site of Neuroendocrine Tumors Affects Outcomes With Cabozantinib - Targeted Oncology
Bone Metastasis in Solid Tumors Market Set to Grow Substantially - openPR.com
Bone Metastasis in Solid Tumors Market Set to Grow Substantially Through 2034, DelveInsight Projects | NanaBis, Actuate Therapeutics, Mabwell Bioscience, Hoffmann-La Roche, Novartis, Upjohn, INSYS - Barchart.com
Will Actuate's Elraglusib Prove To Be A Game Changer In The Fight Against Aggressive Cancers? - RTTNews
1.30%
3.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):